Small-Molecule Peptide Tyr-Phe for MAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical methods are ineffective in treating metabolic-associated fatty liver disease (MAFLD), relying on lifestyle changes that are difficult to maintain, and there is a need for a therapeutic approach to inhibit fat build-up and regulate blood glucose levels.
Innovation Solution
A novel small-molecule peptide with an amino acid sequence of Tyr-Phe or Phe-Tyr, which can be administered to inhibit fat accumulation and regulate glucose metabolism, is developed for use in treating or preventing MAFLD and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifestyle changes (exercise and diet) are implemented to treat MAFLD, then fat build-up can be reduced, but patient compliance is poor and lifestyle changes are difficult to maintain
Solution Approach 1:
The patent introduces a peptide compound as an intermediary substance that mediates between the patient and the need for lifestyle changes. The peptide acts as a therapeutic agent that can inhibit fat build-up and regulate blood glucose levels, providing a pharmacological alternative that reduces the burden on patients to maintain strict lifestyle modifications while still achieving treatment goals
2Reliability
If no clinical treatment method is used, then treatment complexity is low, but treatment effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure and properties of the treatment approach. The peptide compound represents a specific chemical entity with defined amino acid sequences (including Tyr-Phe or Phe-Tyr motifs) that can be synthesized and administered to achieve therapeutic effects, transforming the treatment from generic lifestyle advice to a specific pharmacological intervention with measurable parameters
Data Source
AI summary
A novel small-molecule peptide and a use thereof against metabolic-associated fatty liver disease (MAFLD) are disclosed. The small-molecule peptide has a sequence including Tyr and Phe. The small-molecule peptide has activity in inhibiting fat build-up in the liver, regulating metabolizing enzymes in the liver, and regulating the blood glucose level. The small-molecule peptide can be used to treat or improve MAFLD and MAFLD-related diseases.